Cellceutix Corp. CTIX Archives

TuesdayJun 29, 2010 1:54 pm

Cellceutix Corp. (CTIX.OB) Backed by Seasoned Management Team

Cellceutix Corp. develops small molecule therapies for treatment of cancer, autism and inflammatory disease. The company is supported by a panel of officers and advisors with extensive experience and knowledge in the fields of cancer and genetics, as well as with wide experience in the pharmaceutical business and relative researching, developing and marketing. Most of the company’s efforts center on the company’s lead product Kevetrin, which is in development for drug-resistant cancers. Cellceutix is concluding final studies before applying for FDA approval for human studies. The company’s focus is maintained by a strong management team and a shared commitment to…

ThursdayJun 24, 2010 7:05 am

Cellceutix Corp. (CTIX.OB) Autism Study Shows Increase in Serotonin Levels in Three Areas of the Brain

Cellceutix Corp. announced yesterday after the closing bell that they have completed another study in the research of KM-391, the company's novel compound being developed to treat the core symptoms of autism. Pioneering research in autism treatments, Cellceutix has been making solid progress with pre-clinical research as announced in previous press releases. In the autistic brain, neonatal serotonin depletion and decreased brain plasticity are observed. The Cellceutix team has identified a reliable animal model and has been successful in chemically inducing these characteristics in the model. The data collected to this point has been promising as KM-391 has shown to…

MondayJun 21, 2010 7:52 am

Cellceutix Corp. (CTIX.OB) Research on Kevetrin Showing More Great Results in Destroying Cancer Cells

Cellceutix announced more research data this morning on studies done with Kevetrin™, their leading compound for the treatment of specific stains of multi-drug resistant breast, lung and colon cancers. This series of testing was focused on Kevetrin affecting the life cycle of a specific lung cancer cell and was conducted by the Cellceutix research team at a major cancer hospital in Boston. The data revealed that Kevetrin had a 78% effective rate of G2/M arrest and a 66% increase in apoptosis. To understand the significance of this data, it is important to know what portion of a cell’s life cycle…

FridayJun 18, 2010 10:42 am

Cellceutix Corp. (CTIX.OB): The Baby Blue Chip Presents a Great Investment Opportunity

With over four thousand NASDAQ Bulletin Board listed companies, it can be a bit of a task to research and find the true jewels that present great investment opportunities. No need to keep looking as we are bringing you one today. Cellceutix Corporation trades on the NASDAQ Bulletin Board under the ticker CTIX and is emerging as an industry leader in both autism and multi-drug resistant cancers. When finding a solid biotechnology investment, it is imperative to research three primary requirements: history, pipeline and potential. We will take a look at these three and how Cellceutix Corporation measures up as…

FridayJun 11, 2010 7:52 am

Cellceutix Corp. (CTIX.OB) Emerging as Industry Leader with Autism and Multi-Drug Resistant Cancer Compounds

Cellceutix Corporation, based in Beverly, MA, has been receiving a lot of attention recently with the developments of two of their very special compounds. Cellceutix focuses their attention on the development of small molecules for unmet needs in the field of biotechnology. “Unmet needs” can mean a couple different things. One, it can mean that there is no drug on the market today that approaches a treatment for an illness from a certain clinical perspective. Second, it can mean that the present drugs available are becoming ineffective as cells can develop what is referred to as “resistance” to the standard…

MondayJun 07, 2010 7:38 am

Cellceutix Corp. (CTIX.OB) Expedites Autism Studies in Response to Public Support; Announces Completion of Two Required Safety Pharmacology Studies

Cellceutix Corp. was pleased to announce this morning its acknowledgement of the many emails, phone calls and letters received regarding KM-391, its novel compound for the treatment of autism. In response to the outcries, Cellceutix has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the compound with the results to be released in upcoming weeks. Cellceutix worked with the world-renowned InterEd Faculty of Clinical Research (IFCR) in India to move rapidly in the development of KM-391. The Company's President and Chief Scientific Officer, Dr. Krishna Menon, as Chancellor of IFCR, was able to request expedited…

ThursdayJun 03, 2010 7:45 am

Cellceutix Corp. (CTIX.OB) CFO Partakes in Exclusive Interview to Discuss Autism Drug, Kevetrin(TM) and Various Progressions

Cellceutix Corp. was pleased to announce that its Chief Financial Officer, Leo Ehrlich, has been featured in an interview with leading online financial publication, CEOCFO Interviews and News. Conducted by CEOCFO Senior Editor Lynn Fosse, the interview highlighted the distinctiveness of Cellceutix and the reasons why the company stands out from all other biotech companies in the industry. Mr. Ehrlich discussed the progressions of KM-391, Cellceutix's compound for the treatment of autism, and Kevetrin, which is being developed as a treatment for drug-resistant cancers. He also explained why their autism drug is revolutionary as there is no drug currently available…

WednesdayJun 02, 2010 2:31 pm

Cellceutix Corp. (CTIX.OB) is “One to Watch”

Cellceutix Corp., an emerging bio-pharmaceutical company, is in the early stages of receiving an influx of media attention and widespread notoriety within the pharmaceutical industry due to the promising results shown during the early development of a compound for the treatment of autism, KM-391, and the approaching Phase 1 clinical trials of Kevetrin™, the company's compound for the treatment of drug-resistant cancers. In addition to these two, Cellceutix currently manages a portfolio of six other promising compounds. KM-391, a 100% novel compound, is revolutionary in that it addresses the core issues of autism, unlike the pharmaceuticals presently on the market…

Site Search

Company Search

Tag: Cellceutix Corp. CTIX